#USA #NASDAQ #Karyopharm #XPOVIO #Newton

Karyopharm Therapeutics Unveils Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

On June 1, 2026, Karyopharm Therapeutics Inc., a pioneering force in cancer treatment and listed on Nasdaq under the symbol KPTI, made a significant announcement regarding their personnel strategy aimed at enhancing their specialized human resources. The company revealed that it has granted 1,200 restricted stock units (RSUs) to a new employee as part of its initiatives to attract and retain top talent. This grant was effective as of May 31, 2026, and complies with the Nasdaq Listing Rule 5635(c)(4), which allows for such inducement grants in new employment contexts.

The RSU awards granted by Karyopharm will vest over a three-year period, with a third of the shares eligible to vest on each anniversary of the grant date. The vesting schedule is contingent upon the employee’s continued service to Karyopharm, emphasizing the company's commitment to fostering a stable and engaged workforce. This move is seen as pivotal for Karyopharm as it continues to innovate within the competitive pharmaceutical landscape.

Karyopharm Therapeutics is recognized for its cutting-edge approach to cancer therapies, particularly through its lead product, XPOVIO® (selinexor), which is a first-in-class exportin 1 (XPO1) inhibitor. Targeted at patients with relapsed or refractory multiple myeloma, XPOVIO has demonstrated its efficacy and gained approval for use in the U.S. and various international markets, making it a cornerstone of Karyopharm's therapeutic offerings.

The innovation ethos at Karyopharm isn't limited to their existing therapies. The company is strategically advancing their research into both hematologic and solid tumors, including conditions like myelofibrosis and TP53 wild-type endometrial cancer. With a solid foundation in XPO1 biology, Karyopharm is looking to explore additional opportunities, including potential therapies using next-generation compounds like eltanexor.

Based in Newton, Massachusetts, Karyopharm operates with an efficient and scalable commercial structure that supports its mission to bring groundbreaking cancer therapies to market. The company’s commitment to nurturing talent through strategic equity offerings reflects its broader objective of ensuring a high-performance culture equipped to meet the challenges of cancer care.

As Karyopharm continues its trajectory of growth and innovation, the announcement of this RSU grant underlines the company’s focus not only on therapeutic advancements but also on strategic human resource management. This focus sets the stage for sustained progress in their mission to develop differentiated therapies that can significantly improve patients’ lives in the fight against cancer.

For more information about Karyopharm and its revolutionary products, please visit www.karyopharm.com and follow the company on professional networks like LinkedIn and social media platforms.

Conclusion

Karyopharm Therapeutics' recent inducement grant serves as a testament to its dedication to fostering a strong corporate culture while simultaneously pushing the boundaries of cancer treatment. With an experienced team and a pipeline of promising therapies, Karyopharm is poised to make significant contributions to the pharmaceutical industry in the coming years.